Head-to-Head: which EoE drug fights scarring better?

NCT ID NCT07358234

ENROLLING_BY_INVITATION Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for eosinophilic esophagitis (EoE): swallowed budesonide (Eohilia) and injected dupilumab (Dupixent). Researchers want to see which one better improves esophageal diameter and reduces scarring after 12 weeks. The trial enrolls 60 adults with active EoE at Mayo Clinic locations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: budesonide oral suspension and dupilumab injection
What this could lead to: If successful, this could show which treatment is more effective at reducing esophageal scarring and improving swallowing in EoE patients.
What could go wrong: This is a very early-phase trial with only 60 participants, so results may not apply to everyone. Both drugs have side effects, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS (EOE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC ESOPHAGITIS (EOE)

Contacts and locations

Locations

Mayo Clinic

Scottsdale, Arizona, 85259, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.